Literature DB >> 26636714

Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer.

Xin Dai1, Wei Fan1, Yingzhe Wang1, Lijie Huang2, Ying Jiang1, Lei Shi3, DeAngelo Mckinley1, Wen Tan2, Chalet Tan1.   

Abstract

In the present study, we synthesized a novel cationic copolymer composed of polyethylene glycol 5000 (PEG5K), vitamin E (VE), and diethylenetriamine (DET) at 1:4:20 molar ratio. The resulting PEG5K-VE4-DET20 copolymer formed nanoassemblies when mixed with the neutral PEG5K-VE4 copolymer at 1:8 weight ratio, which were investigated as the nanocarriers for combined delivery of paclitaxel and let-7b mimic. We found that the PEG5K-VE4-DET20 nanoassemblies could entrap paclitaxel for an extended period and burst release the drug in the presence of cathepsin B, demonstrating the biodegradability of the copolymers. At N/P ratio of 12:1, the PEG5K-VE4-DET20 nanoassemblies formed stable polyplexes with let-7b mimic, which were efficiently taken up by tumor cells and underwent endosomal escape. In non-small cell lung cancer A549 cells that harbor mutant KRAS, paclitaxel and let-7b mimic-loaded nanoassemblies (N-PTX/let-7b) markedly potentiated the cytotoxicity of paclitaxel, induced apoptosis, and diminished the invasiveness of tumor cells. In mice bearing subcutaneous A549 xenografts, intravenous administration of N-PTX/let-7b retarded tumor growth more efficaciously than Taxol. Our study demonstrates the promise of the PEG5K-VE4-DET20 nanoassemblies for concurrent delivery of hydrophobic drugs and miRNA mimics.

Entities:  

Keywords:  chemosensitizer; drug delivery; let-7; microRNA replacement; nanoassembly; paclitaxel

Mesh:

Substances:

Year:  2015        PMID: 26636714     DOI: 10.1021/acs.molpharmaceut.5b00756

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  14 in total

Review 1.  Decoding microRNA drivers in atherosclerosis.

Authors:  Tanwi Vartak; Soundharya Kumaresan; Eoin Brennan
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

Review 2.  A perspective to weaponize microRNAs against lung cancer.

Authors:  Dhanashree Murugan; Loganathan Rangasamy
Journal:  Noncoding RNA Res       Date:  2022-09-29

Review 3.  microRNA-based diagnostic and therapeutic applications in cancer medicine.

Authors:  Lorenzo F Sempere; Asfar S Azmi; Anna Moore
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-05-17       Impact factor: 9.957

4.  Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma.

Authors:  Yongmeng Li; Rui Dong; Ming Lu; Chuanle Cheng; Zitong Feng; Renchang Zhao; Jinghui Liang; Jingyi Han; Jin Jiang; Meng Xu-Welliver; Stéphane Renaud; Hui Tian
Journal:  Transl Lung Cancer Res       Date:  2021-04

5.  Dual-Function Polymeric HPMA Prodrugs for the Delivery of miRNA.

Authors:  Zheng-Hong Peng; Ying Xie; Yan Wang; Jing Li; David Oupický
Journal:  Mol Pharm       Date:  2017-01-30       Impact factor: 4.939

6.  Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice.

Authors:  Virender Kumar; Vaibhav Mundra; Yang Peng; Yingzhe Wang; Chalet Tan; Ram I Mahato
Journal:  Theranostics       Date:  2018-07-05       Impact factor: 11.556

Review 7.  Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-07-27

Review 8.  Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.

Authors:  Svetlana Miroshnichenko; Olga Patutina
Journal:  Front Pharmacol       Date:  2019-05-16       Impact factor: 5.988

Review 9.  Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer.

Authors:  Evgeny Chirshev; Kerby C Oberg; Yevgeniya J Ioffe; Juli J Unternaehrer
Journal:  Clin Transl Med       Date:  2019-08-28

Review 10.  Prodrug Strategies for Paclitaxel.

Authors:  Ziyuan Meng; Quanxia Lv; Jun Lu; Houzong Yao; Xiaoqing Lv; Feng Jiang; Aiping Lu; Ge Zhang
Journal:  Int J Mol Sci       Date:  2016-05-23       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.